Top Mid Cap Stocks to Buy

Uranium Energy Corp (UEC) continues to solidify its path to market leadership, with the successful commencement of production at Burke Hollow on April 8, 2026, marking the world's newest U.S. ISR uranium mine. This pivotal event, a direct confirmation of a key milestone outlined in the previous analysis, significantly de-risks its growth trajectory. While Q2 FY2026 revenue of $20.2M showed a year-over-year decline against a prior, specific contract-boosted quarter, it successfully beat estimates and aligns with the strategy of ramping up new production. The company is strategically positioned to capitalize on global energy security and decarbonization trends, maintaining a strong balance sheet and a clear forecast for profitability inflection in FY22027. This operational progress and strategic execution further enhance confidence in UEC's credible 10x growth potential within 3-5 years.

Apogee Therapeutics demonstrates significantly strengthened 10x potential. The positive Phase 2 APEX Part A 52-week data for APG777 in Atopic Dermatitis is a critical de-risking event, validating its differentiated extended half-life and strong efficacy. This substantially bolsters its competitive advantage and clarifies future multi-billion dollar growth drivers. Furthermore, the successful $350M public offering significantly improves its cash runway, reinforcing its financial health. Leadership continues to deliver on milestones, fostering robust institutional sentiment despite insider selling under 10b5-1 plans. While high clinical risk remains inherent to biotech, these recent developments provide strong conviction for substantial market re-rating within 3-5 years. The stock has run up, but long-term catalysts are stronger than ever.

Atour Lifestyle Holdings Ltd (ATAT) continues to exhibit robust growth and strategic excellence, justifying a strong investment score. The company's Q4 and FY 2025 results show impressive revenue growth (33.8-35.1% YoY), fueled by its highly scalable 'manachised' model and rapid network expansion. Profitability remains healthy with a 46.96% ROE and strong operating cash flow. The newly adopted 3-year dividend policy (≥50% of prior-year net income) signals confidence and commitment to shareholder returns. While trading at a premium, ATAT's dominant position in China's premium lifestyle hotel segment, combined with its burgeoning retail business, underpins significant upside potential. Regulatory risks inherent to Chinese ADRs persist but are well-managed and transparently disclosed, without any new adverse developments since the last analysis.

iRhythm Holdings continues to demonstrate strong execution in the remote cardiac monitoring market. The Zio platform, with its AI-driven insights and superior patient experience, is expanding its competitive moat. Financial performance is steadily improving, with robust revenue growth pushing the company towards sustained profitability. Leadership has consistently delivered on strategic milestones, particularly in the adoption of Zio AT and initial international expansion. While regulatory and competitive challenges persist, IRTC's technological lead, established reimbursement, and clear growth catalysts position it for substantial market share gains and potential 10x growth within the next 3-5 years. No material changes have occurred since the last analysis to warrant a score adjustment.

Palomar Holdings (PLMR) continues to present exceptional 10x growth potential within 3-5 years, leveraging its tech-enabled underwriting to dominate underserved, catastrophe-exposed P&C markets. Q4 2025 results showcased robust revenue (+62.7% YoY) and EPS growth (+47.4% YoY), alongside strong margins and ROE. The imminent Q1 2026 earnings, with ambitious consensus revenue estimates, will be a key near-term indicator of continued aggressive expansion. While insider selling by the CEO and President has been observed, it does not materially undermine the strong fundamental thesis of market leadership, expanding competitive advantages, and a highly scalable business model, all reinforced by positive analyst sentiment and institutional investment. The enduring hard market conditions and avenues for product diversification further solidify its growth trajectory, positioning PLMR for substantial value appreciation.